Avalo Therapeutics
AVTX
125 hedge funds and large institutions have $1.31B invested in Avalo Therapeutics in 2026 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 47 increasing their positions, 15 reducing their positions, and 27 closing their positions.
522% more capital inflows, than outflows
Capital inflows: $753M | Capital outflows: $121M
213% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 15
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
104% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 27
73.92% more ownership
Funds ownership: 58% → 131.92% (+74%)
29% more funds holding
Funds holding: 97 → 125 (+28)
22% more call options, than puts
Call options by funds: $9.7M | Put options by funds: $7.97M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$63.8M |
| 2 |
Deep Track Capital
Greenwich,
Connecticut
|
+$57.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$44.5M |
| 4 |
TCG Crossover Management
Palo Alto,
California
|
+$36M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$35.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$32.3M |
| 2 |
Millennium Management
New York
|
-$12.5M |
| 3 |
RTW Investments
New York
|
-$10.8M |
| 4 |
OrbiMed
New York
|
-$7.09M |
| 5 |
Jennison Associates
New York
|
-$7.03M |
AVTX Hedge Fund Activity: Q2 2026 in Review
125 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q2 2026, worth a combined $1.31B — up 182% from $464M a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new AVTX positions and 27 closed out — a net gain of 28 holders — while 47 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $63.8M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $32.3M sold.
- 125 institutional investors held Avalo Therapeutics (AVTX) as of Q2 2026, up from 97 in Q1 2026.
- Funds reported $1.31B of Avalo Therapeutics stock for Q2 2026, up 182% quarter-over-quarter.
- 55 funds opened new Avalo Therapeutics positions in Q2 2026 and 27 closed out, a net change of +28 holders.
- The largest Avalo Therapeutics buyer in Q2 2026 was BlackRock, an estimated $63.8M added.
- The largest Avalo Therapeutics seller in Q2 2026 was T. Rowe Price Investment Management, an estimated $32.3M sold.
Based on aggregated 13F filings for Q2 2026.